ATS 2019 Virtual Final Program

3:15 Novel TB Vaccines: Correlates of Protection and Lessons From Clinical Trials M. Ruhwald, MD, PhD, Copenhagen, Denmark 3:35 Lessons from the Field: TB Infection State Profiling and Biomarker-Based TB Prevention Strategies T.J. Scriba, PhD, Cape Town, South Africa 3:55 Update in Diagnostics and Therapeutic Interventions in Latent TB Infection in Low TB Endemic Areas P. Escalante, MD, MSc, Rochester, MN BEHAVIORAL • CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 C90 BENCH TO BEDSIDE: HOW DIETARY N3-PUFAS MODULATE THE PULMONARY RESPONSE TO ENVIRONMENTAL EXPOSURES Assemblies on Environmental, Occupational and Population Health; Allergy, Immunology and Inflammation; Respiratory Cell and Molecular Biology 2:15 p.m. - 4:15 p.m. KBHCCD Room D163/D165/D170/D172 (Level 1) Target Audience Basic and clinical researchers and clinicians interested in learning about emerging literature indicating a pivotal role for diet and n-3 PUFAs in environmental lung diseases Objectives At the conclusion of this session, the participant will be able to: • understand the potential for diet and n-3 PUFAs as a therapeutic option against the adverse health outcomes from environmental exposures; • understand the underlying mechanisms by which n-3 PUFAs may mitigate the effects of environmental exposures on relevant pulmonary health outcomes; • compare and contrast the findings in basic, translational, and clinical studies related to the effects of n-3 PUFA intake on pulmonary response to environmental exposures. Environmental exposures (both ambient and occupational) contribute to the onset and exacerbation of lung diseases. Defining novel therapeutic strategies to limit the adverse health effects of environmental exposures is critical. Diet is increasingly recognized as an important factor in immune health. Within diet, n-3 polyunsaturated fatty acids (PUFAs) are a critical nutrient that has demonstrated immunomodulatory properties in inflammatory diseases such as obesity, cardiovascular diseases, and arthritis. A novel paradigm has been proposed linking n-3 PUFA intake and reductions in environmental lung diseases. This session will introduce novel mechanisms wherein diet, with a focus on n-3 PUFAs, can mitigate effects of environmental respiratory exposures. Chairing: K.M. Gowdy, BS, MS, PhD, Greenville, NC J.G. Wagner, MBA, PhD, East Lansing, MI E. Brigham, MD, MHS, Baltimore, MD 2:15 Fatty Acid Intake in the United States C. Hanson, PhD, Omaha, NE 2:35 Silica-Triggered Lupus Flares, Pulmonary Powerhouses of Autoimmunity, and Dietary Lipid Interventions for Prevention and Treatment J.R. Harkema, DVM, PhD, ATSF, East Lansing, MI 2:55 Dietary N-3 PUFAs Modulates Ozone Induced Pulmonary Immunity K.M. Gowdy, BS, MS, PhD, Greenville, NC 3:15 Supplementation with n-3 PUFAs Ameliorate Adverse Cardiovascular Health Effects of Air Pollution Exposure in Human Volunteers J.M. Samet, MPH, PhD, Chapel Hill, NC 3:35 Dust and Diet: Environmental Factors Impacting Lung Health T.M. Nordgren, PhD, Riverside, CA 3:55 Dietary Influences on the Response to Particulate Matter Exposure: Asthma and COPD N.N. Hansel, MD, MPH, Baltimore, MD BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 C91 IMPROVING CARE QUALITY WHILE REDUCING COST: IS HIGH VALUE CARE FOR COPD ACHIEVABLE? Assemblies on Behavioral Science and Health Services Research; Clinical Problems; Nursing 2:15 p.m. - 4:15 p.m. KBHCCD Room C155-C156 (Level 1) Target Audience Inter-professional providers of care for patients with lung disease including those interested in learning about emerging evidence for effective strategies to provide high value care for patients with COPD Objectives At the conclusion of this session, the participant will be able to: • distinguish value based care from cost effectiveness; • identify high value interventions that could be implemented in their institutions; • learn about the diverse stakeholder perspectives in value-based care. COPD is a frequent target of calls to improve the value of health care. Yet, improving value requires meeting the often-opposing goals of increasing quality while reducing costs. In this session, experts will discuss the evidence surrounding several areas to improve the value of care provided during COPD-related hospitalizations. Specifically, we will discuss recent science addressing the value implications of 1)where we provide care for acute exacerbations, 2) how we pay for it, and 3)how we protect patients from readmissions after discharge. Chairing: V.G. Press, MD, MPH, Chicago, IL A.J. Admon, MD, MPH, Ann Arbor, MI L. Myers, MD, Boston, MA ATS 2019 • Dallas, TX TUESDAY • MAY 21 295 TUESDAY AFTERNOON